cognito therapeutics

Cognito Therapeutics Receives FDA Breakthrough Device Designation for Light and Sound Therapy in Alzheimer’s Disease

CAMBRIDGE, MASSACHUSSETTS — Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders, announced this week that its lead product has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the treatment of cognitive and functional symptoms associated with Alzheimer’s disease.…

Read More